In a 50-year-old man with pulmonary hypertension, heart failure with reduced ejection fraction (EF 35%) and peripheral arterial disease who tolerated sacubitril/valsartan (Entresto) without hypotension, which medication—sildenafil, carvedilol, or spironolactone—should be restarted first?

Restart Carvedilol First

In this patient who has successfully restarted Entresto without hypotension, carvedilol should be restarted first, followed by spironolactone, with sildenafil restarted last due to the significant additive hypotensive risk when combined with sacubitril/valsartan.

Rationale for Sequencing

Why Carvedilol First

Beta-blockers are foundational therapy in HFrEF with the highest priority for mortality reduction. The 2022 AHA/ACC/HFSA guidelines emphasize that beta-blockers (specifically carvedilol, bisoprolol, or metoprolol succinate) reduce mortality and hospitalization in HFrEF and should be initiated early, even in-hospital once patients are stabilized 1. The guideline explicitly states these agents improve LVEF, reduce symptoms, and provide high economic value, with benefits maintained across diverse patient populations 1.

Key implementation points:

• Start at low dose and uptitrate gradually
• Monitor for hypotension, but the prior tolerance of Entresto suggests adequate volume status
• The mortality benefit persists even if symptoms don't immediately improve
• Should not be delayed waiting for symptom resolution

Why Spironolactone Second

Mineralocorticoid receptor antagonists are Class 1A recommendations for HFrEF with NYHA Class II-IV symptoms. The 2022 guidelines recommend spironolactone or eplerenone to reduce morbidity and mortality when eGFR >30 mL/min/1.73 m² and potassium <5.0 mEq/L 1.

Critical monitoring requirements:

• Check potassium and renal function at 1 week, then 4 weeks, then regularly
• Start at 25 mg daily, increase to 50 mg after one month if tolerated
• The combination with Entresto increases hyperkalemia risk—this is the main concern, not hypotension
• Discontinue if potassium cannot be maintained <5.5 mEq/L 1

Why Sildenafil Last

Sildenafil poses the highest hypotension risk when combined with sacubitril/valsartan. A 2018 pharmacokinetic/pharmacodynamic study demonstrated that coadministration of sildenafil with sacubitril/valsartan resulted in an additional blood pressure reduction of -5/-4/-4 mmHg (SBP/DBP/MAP) beyond sacubitril/valsartan alone 2. The FDA label for Entresto explicitly warns about hypotension risk and recommends dose adjustment of concomitant antihypertensive drugs 3.

Specific approach for sildenafil restart:

• Wait until carvedilol and spironolactone are stable (at least 2-4 weeks)
• Ensure blood pressure is adequate (SBP consistently >100-110 mmHg)
• Start at lowest dose (20 mg three times daily per FDA approval for PAH) 4, 5
• Monitor blood pressure closely, particularly 1-2 hours post-dose
• The 2014 CHEST guidelines support sildenafil for WHO FC III PAH to improve exercise capacity 4

Common Pitfalls to Avoid

1. Don't restart all medications simultaneously—this makes it impossible to identify which agent causes problems if hypotension recurs

2. Don't skip beta-blockers due to hypotension concerns—the mortality benefit is too significant, and low-dose initiation with gradual uptitration is usually well-tolerated once volume status is optimized

3. Don't forget potassium monitoring—the combination of Entresto + spironolactone significantly increases hyperkalemia risk; this is more likely to cause problems than hypotension

4. Don't use sildenafil doses higher than studied—while doses up to 80 mg TID have been studied, start at 20 mg TID given the drug interaction with sacubitril/valsartan 4

5. Ensure adequate volume status—if the patient required high-dose diuretics previously, optimize volume status before adding multiple blood pressure-lowering agents 3

Monitoring Strategy

• Week 1-2: Restart carvedilol at low dose (3.125 mg BID), monitor BP and heart rate
• Week 2-3: Add spironolactone 25 mg daily, check potassium and creatinine at 1 week
• Week 4-6: Once stable, consider sildenafil 20 mg TID with close BP monitoring
• Ongoing: Uptitrate carvedilol toward target dose (25 mg BID) over subsequent weeks as tolerated

This sequential approach prioritizes the medications with the strongest mortality benefit (carvedilol, spironolactone) while managing the significant hypotensive risk of combining sildenafil with sacubitril/valsartan.